Survodutide Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous Frequency: Once weekly Dose Range: Phase 2 tested 0.3-6.0 mg weekly; optimal dose being determined in Phase 3 Cycle Length: Phase 2 was 46-48 weeks; Phase 3 ongoing Timing: Same day each week
Storage
Lyophilized: -20 °C (-4 °F) Reconstituted: 2-8 °C (35.6-46.4 °F) Shelf Life: 28 days
Injection Sites
Abdomen, Thigh
Safety & Contraindications
Safety: GI adverse events (nausea, vomiting, diarrhea) similar to other incretin-based therapies Heart rate increases observed (class effect) Dose-dependent tolerability — titration essential
Contraindications: Not established (investigational); Likely similar to GLP-1 class: MTC history, MEN2, pregnancy
Related Research News
Survodutide Shows Renal and Metabolic Gains in DKD Mouse Model at ECO 2026
Researchers presented data at the European Congress on Obesity (ECO) on survodutide's effects in a mouse model of advanced diabetic kidney disease (DKD). The drug improved kidney injury markers like albuminuria and glomerulosclerosis, along with metabolic measures such as body weight and glucose levels. These results suggest potential for broader applications if confirmed in human studies.
Daily Pill Could Tackle Dreaded Ozempic Rebound
A daily pill could serve as the answer to the dreaded Ozempic rebound. Retatrutide and survodutide appear in this context within clinical trials. This approach targets a common challenge after Ozempic treatment.